184 related articles for article (PubMed ID: 10342361)
1. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas.
Cetani F; Tonacchera M; Pinchera A; Barsacchi R; Basolo F; Miccoli P; Pacini F
J Endocrinol Invest; 1999 Apr; 22(4):273-8. PubMed ID: 10342361
[TBL] [Abstract][Full Text] [Related]
2. Activating mutations of the TSH receptor in differentiated thyroid carcinomas.
Russo D; Arturi F; Schlumberger M; Caillou B; Monier R; Filetti S; Suárez HG
Oncogene; 1995 Nov; 11(9):1907-11. PubMed ID: 7478621
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
[TBL] [Abstract][Full Text] [Related]
4. Mutation of the PIK3CA gene in anaplastic thyroid cancer.
García-Rostán G; Costa AM; Pereira-Castro I; Salvatore G; Hernandez R; Hermsem MJ; Herrero A; Fusco A; Cameselle-Teijeiro J; Santoro M
Cancer Res; 2005 Nov; 65(22):10199-207. PubMed ID: 16288007
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy.
Máximo V; Lima J; Soares P; Botelho T; Gomes L; Sobrinho-Simões M
Mitochondrion; 2005 Oct; 5(5):333-40. PubMed ID: 16183030
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of thyrotropin receptor gene suggests a high-risk subgroup for oncocytic adenoma.
Mirebeau-Prunier D; Guyétant S; Rodien P; Franc B; Baris O; Rohmer V; Reynier P; Tourmen Y; Malthièry Y; Savagner F
Eur J Endocrinol; 2004 Mar; 150(3):269-76. PubMed ID: 15012610
[TBL] [Abstract][Full Text] [Related]
7. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.
Tonacchera M; Vitti P; Agretti P; Ceccarini G; Perri A; Cavaliere R; Mazzi B; Naccarato AG; Viacava P; Miccoli P; Pinchera A; Chiovato L
J Clin Endocrinol Metab; 1999 Nov; 84(11):4155-8. PubMed ID: 10566665
[TBL] [Abstract][Full Text] [Related]
8. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
9. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.
Lado-Abeal J; Celestino R; Bravo SB; Garcia-Rendueles ME; de la Calzada J; Castro I; Castro P; Espadinha C; Palos F; Soares P; Alvarez CV; Sobrinho-Simões M; Cameselle-Teijeiro J
Endocr Relat Cancer; 2010 Sep; 17(3):599-610. PubMed ID: 20427420
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
[TBL] [Abstract][Full Text] [Related]
11. Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases.
Führer D; Tannapfel A; Sabri O; Lamesch P; Paschke R
Endocr Relat Cancer; 2003 Dec; 10(4):591-600. PubMed ID: 14713269
[TBL] [Abstract][Full Text] [Related]
12. Cell kinetics, DNA content and TSH receptor-adenylate cyclase system in differentiated thyroid cancer.
Chang TC; Kuo SH; Liaw KY; Chang CC; Chen FW
Clin Endocrinol (Oxf); 1988 Nov; 29(5):477-84. PubMed ID: 3253029
[TBL] [Abstract][Full Text] [Related]
13. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
[TBL] [Abstract][Full Text] [Related]
14. No evidence of thyrotropin receptor and G(s alpha) gene mutation in high iodine uptake thyroid carcinoma.
Bourasseau I; Savagner F; Rodien P; Duquenne M; Reynier P; Guyetant S; Bigorgne JC; Malthièry Y; Rohmer V
Thyroid; 2000 Sep; 10(9):761-5. PubMed ID: 11041453
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
16. G protein and thyrotropin receptor mutations in thyroid neoplasia.
Esapa C; Foster S; Johnson S; Jameson JL; Kendall-Taylor P; Harris PE
J Clin Endocrinol Metab; 1997 Feb; 82(2):493-6. PubMed ID: 9024242
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations in all stages of thyroid carcinomas.
Zou M; Shi Y; Farid NR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
[TBL] [Abstract][Full Text] [Related]
18. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas.
Park HJ; Kim JY; Park KY; Gong G; Hong SJ; Ahn IM
Thyroid; 2000 Mar; 10(3):211-7. PubMed ID: 10779135
[TBL] [Abstract][Full Text] [Related]
19. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
20. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
